Evercore ISI lowered the firm’s price target on Heron Therapeutics to $10 from $15 and keeps an Outperform rating on the shares. Despite it’s stronger efficacy and ease-of-use, Zynrelef "continues to struggle," posting $3.9M in Q4 and projecting growth of only 10% quarter-over-quarter in Q1, the analyst tells investors. Heron did a good job reigning in spending, but it still has a financing overhang to address in addition to $150M of convertible notes due May 2026, notes the firm, which is adding "a highly dilutive near-term financing" to its model, but Evercore still believes that Heron can execute through the challenges and inflect Zynrelef and Aponvie to "become a meaningfully profitable business."
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HRTX:
- Heron Therapeutics Dives on Zynrelef Troubles
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics reports Q4 EPS (17c), consensus (28c)
- Heron announces CMS granted pass-through payment status for APONVIE
- Heron says CMS granted pass-through payment status for Aponvie